Deoxyribonucleic acid methylation profiling has also emerged as a robust adjunct for distinguishing intimal sarcomas from histologically similar sarcomas, particularly in MDM2-negative cases.12) Alterations in cell cycle regulators, such as p16, and oncogene activation, including c-MYC or KIT/PDGFRA, further suggest potential therapeutic implications.15) These molecular insights not only facilitate accurate diagnosis but may also guide future targeted approaches in PAIS. This evidence concerns the gene MDM2 and sarcoma.